BeOne Medicines Ltd. American Depositary Shares
ONC · Nasdaq
$353.83+$71.7826.13%
$353.83$0.000.00%
ONC · Nasdaq
BeOne Medicines is a medicines company, but the supplied evidence does not identify its specific therapies, business segments, customer mix, geographic exposure, or revenue contribution by segment. The available financial record shows that it generated $5.3 billion of revenue and $0.3 billion of net income in fiscal 2025, compared with $3.8 billion of revenue and a $0.6 billion net loss in fiscal 2024. Thus, the evidence supports a materially larger and profitable business in 2025, but it does not support a fuller description of products, customers, or operating scale.
BeOne Medicines fell $7.45, or 2.25%, from $330.46 to $323.01 over the supplied interval. The decline was steady through July 28 to August 3, with closes dropping to $313.77 and no material reversal until the final session. On August 4, the stock rebounded $9.24, recovering much of the prior day’s loss but not the week’s net decline. The supplied evidence identifies no company-specific announcement, earnings release, contract, or regulatory event to explain the move. The only related item is a Zacks preview of second-quarter estimates, which provides no reported results or concrete catalyst. No broader market context is supplied.
